



UNITED STATES GOVERNMENT BY COMMERCE
UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR/APPLICANT		ATTORNEY DOCKET NO.
-----------------	-------------	--------------------------------	--	---------------------

10809509.449 03/28/00 ADYAGI K 594-352USWO

023552
MERCHANT & GOULD
P O BOX 2903
MINNEAPOLIS MN 55402-0903

HM22/0105

EXAMINER

WORTMAN, D

ART. UNIT

PAPER NUMBER

1648
1648

7

DATE MAILED:
01/05/01

Please find below a communication from the EXAMINER in charge of this application.

This application contains sequence disclosures that are encompassed by the definitions for nucleic acid and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application is a **Please find below and/or attached an Office communication concerning this application or proceeding** with Requirements For Patent Applications Containing Nucleotide Sequence and Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence disclosure in 37 CFR 1.821-1.823 before the application can be examined under 37 CFR 1.13. **Commissioner of Patents and Trademarks**

At least one even C&R is given C&R 108-109 from the mailing date of this Office communication until the application is abandoned or rejected under 37 CFR 1.13. Failure to comply with those requirements will result in ABANDONMENT of the application under 37 CFR 1.821(a)(2). Disclosures of nucleic acid and/or amino acid sequences must be accompanied by a statement under the provisions of 37 CFR 1.13(a)(1) Dated and signed by the inventor(s). Applicant is expected to return a copy of the attached Notice to Examiner and the Office.

Inquiry concerning this communication and/or other communications from the Office should be directed to Examiner W. Wortman whose telephone number is (703) 308-1032. If the examiner can no longer be reached, inquiries should be directed to Supervisor, Proc. Examining Div. (703) 308-1037. The fax number for the Office communication and/or proceeding is (703) 308-1743.

An inquiry of a general nature or relating to the status of this application should be directed to the Group Director whose telephone number is (703) 308-1466.

BEST AVAILABLE COPY

Jan 5, 2001
Walter C. Wortman, P.T.O.
Primary Examiner

Jan 5, 2001



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/509449			

EXAMINER	
ART UNIT	PAPER NUMBER
1648	7

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Applicant is given ONE MONTH from the mailing date of this communication within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Wortman whose telephone number is (703) 308-1032. If the examiner cannot be reached, inquiries can be directed to Supervisory Patent Examiner James Housel whose telephone number is (703) 308-4027. The fax number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.



Donna C. Wortman, Ph.D.
Primary Examiner

January 4, 2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: _____

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE